• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Pfizer Shares Still Attractive

    A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.

  2. Significant Upside for Pharma Stock Prices, Dividends

    Pharmaceutical firms' adept handling of patent expirations has boosted investors' opinions of the sector, says Morningstar's Damien Conover.

  3. Better Days Ahead for Pharma Firms

    Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover.

  4. Even After Patent Cliff, Pfizer Is Undervalued

    A new ROIC-focused process for compound development plus the value of Pfizer's other businesses add up to a fair value well in excess of $14, says RS Investments manager Joe Wolf.

  1. Pfizer PFE Q4 2012 Earnings Call Transcript

    Good day, everyone and welcome to Pfizer's Fourth Quarter 2012 Earnings Conference Call. Today's call is being recorded.

  2. Emerging Nations: A Blossoming Field For Drug and Medical-Device Firms

     

  3. Schwab Sector Views: Consumer Concerns

     

  4. Breaking Bad Behaviors

     

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.